427 Results Found

Merck Announces First-Quarter 2020 Financial Results

First-Quarter 2020 Worldwide Sales Were $12.1 Billion, an Increase of 11%; Excluding the Impact from Foreign Exchange, Sales Grew 13% KEYTRUDA Sales Grew 45% to $3.3 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 46% Human Health Vaccines Sales Grew 14% to $2.2 Billion, Including the Effect of Timing; Excluding the Impact from Foreign Exchange, Sales Grew 16% First-Quarter 2020 GAAP EPS Was $1.26; First-Quarter Non-GAAP EPS Was $1.50 Company is Active in COVID-19-Related Antiviral and Vaccine Research Due to the Impact of COVID-19, Company Lowers 2020 Full-Year Revenue Range to be Between $46.1 Billion and $48.1 Billion, Including a Negative Impact from Foreign Exchange of Approximately 2.5% Due to the Impact of COVID-19, Company Lowers 2020 Full-Year GAAP EPS Range to be Between $4.12 and $4.32; Lowers 2020 Full-Year Non-GAAP EPS Range to be Between $5.17 and $5.37, Including a Negative Impact from Foreign Exchange of Approximately 3.5% Merck (NYSE: MRK), known as

Merck named to Forbes Just 100 list for “doing right by America”

We are excited to announce that Merck has been named #30 on Forbes and JUST Capital’s Just 100 list, a ranking of publicly traded American corporations that are leading the way with regard to the issues that Americans care about the most, including: worker pay and treatment, customer respect, environmental impact, community involvement, and ethical and diverse leadership.   The […]

search result image

Merck Asks Social Media Companies to do as Much as They Can to Stop Hate Speech, Racism and Discrimination; Merck to Stop Advertising on Facebook and Instagram, Assess Responses from Facebook and Monitor Actions

KENILWORTH, N.J. July 2, 2020 – Merck embraces our responsibility to be a force for good in the world – both through our medicines and vaccines, and through our broader actions to address inequities and to create an environment where all people are valued and respected. Diversity and inclusion are fundamental to the way Merck operates and to our mission to save and improve lives. As a company, we are committed to stopping hate speech, racism and discrimination wherever we can. As part of that commitment, we are calling on social media companies to do as much as they can to stop hate speech, racism and discrimination, and to create social media platforms that encourage sharing of accurate information. We have decided to stop our advertising on Facebook and Instagram. We are assessing the responses from Facebook and will be monitoring the actions they take, and we will do the same across other media platforms. Merck will continue to be a leader in advocating for diversity

Answering your most pressing questions on antimicrobial resistance

As the world battles the COVID-19 pandemic, there is also the growing threat of antibiotic resistance – bacteria that are not killed by standard antibiotics and thrive in hospital settings. Dr. Black breaks down antibiotic resistance and Merck’s role in exploring how we fight bacteria in entirely new ways as we think beyond the pandemic. […]

search result image

Suppliers

Product service area Description Capital procurement Capital equipment Engineering & construction services Environmental & waste management Industrial maintenance MRO Engineering construction services Direct materials Production materials, packaging toll Energy Fuels and utilities Professional services Professional services HR, benefits & training Finance, banking & corporate insurance Site & commercial services Site services Travel & transportation Meeting […]

U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 years of age and older. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action date, of July 18, 2021. The European Medicines Agency is also reviewing an application for licensure of V114 in adults. “Invasive pneumococcal disease in adults is on the rise in many countries, driven by highly-invasive serotypes including serotype 3, which is included in the currently licensed pneumococcal conjugate vaccine, as well as serotypes not included, such as serotypes 22F and 33F,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “Building on our nearly 40 years

1-10 of 427